Modafinil

Generic Name: Modafinil

Brand Names: Provigil

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅NO_₂S

CAS Number: 68693-11-8

Unique Ingredient Identifier: R3UK8X3U3D

Background: Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...

Indication: To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance

Associated Therapies: -

Clinical Trials

A Dose Ranging Study of Modafinil for Methamphetamine Dependence

Phase 2

Conditions: Substance Dependence
Amphetamine Dependence

First Posted Date: 2008-03-06

Last Posted Date: 2011-06-22

Lead Sponsor: California Pacific Medical Center Research Institute

Target Recruit Count: 90

Registration Number: NCT00630097

Locations: 🇺🇸
CPMC, San Francisco, California, United States

Modafinil Treatment for Sleep/Wake Disturbances in Older Adults

Phase 4

Terminated

Conditions: Insomnia
Alzheimer Disease
Sleep Initiation and Maintenance Disorders

Interventions: Drug: modafinil

First Posted Date: 2008-02-29

Last Posted Date: 2019-10-28

Lead Sponsor: VA Palo Alto Health Care System

Target Recruit Count: 2

Registration Number: NCT00626210

Locations: 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States

Modafinil for Treatment of Fatigue in ALS Patients

Phase 4

Completed

Conditions: Fatigue

Interventions: Drug: Modafinil
Drug: Placebo

First Posted Date: 2008-02-13

Last Posted Date: 2012-02-20

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 32

Registration Number: NCT00614926

Locations: 🇺🇸
New York State Psychiatric Institute-Columbia University, New York, New York, United States

Stress and Medication Effects on Cocaine Cue Reactivity

Phase 2

Completed

Conditions: Cocaine Related Disorders

Interventions: Drug: Placebo
Drug: Modafinil
Drug: Guanfacine

First Posted Date: 2008-02-12

Last Posted Date: 2018-06-04

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 109

Registration Number: NCT00613015

Locations: 🇺🇸
Medical University of South Carolina-GCRC, Charleston, South Carolina, United States

Use of Modafinil in the Treatment of Tinnitus

Phase 1

Terminated

Conditions: Tinnitus

Interventions: Other: Placebo
Drug: Modafinil

First Posted Date: 2008-01-11

Last Posted Date: 2015-10-08

Lead Sponsor: University of Arkansas

Target Recruit Count: 7

Registration Number: NCT00591019

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Modafinil, Sleep, and Cognition in Cocaine Dependence

Not Applicable

Completed

Conditions: Cocaine Dependence
Substance-induced Sleep Disorder
Substance-induced Cognitive Disorder

Interventions: Drug: Placebo
Drug: Modafinil

First Posted Date: 2007-12-28

Last Posted Date: 2012-09-14

Lead Sponsor: Yale University

Target Recruit Count: 44

Registration Number: NCT00582491

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: modafinil

First Posted Date: 2007-12-14

Last Posted Date: 2009-08-12

Lead Sponsor: North Suffolk Mental Health Association

Target Recruit Count: 40

Registration Number: NCT00573417

Locations: 🇺🇸
Freedom Trail Clinic, Boston, Massachusetts, United States

Safety and Tolerability of Modafinil for Methamphetamine Dependence

Phase 2

Completed

Conditions: Methamphetamine Dependence

First Posted Date: 2007-12-07

Last Posted Date: 2010-10-05

Lead Sponsor: University of Arkansas

Target Recruit Count: 8

Registration Number: NCT00569374

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Modafinil

First Posted Date: 2007-10-19

Last Posted Date: 2009-02-24

Lead Sponsor: Veterans Medical Research Foundation

Target Recruit Count: 26

Registration Number: NCT00546403

Locations: 🇺🇸
VA Healthcare System, Department of Psychiatry, San Diego, California, United States

A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence

Phase 2

Completed

Conditions: Methamphetamine Addiction

Interventions: Drug: modafinil

First Posted Date: 2007-10-03

Last Posted Date: 2013-06-03

Lead Sponsor: California Pacific Medical Center Research Institute

Target Recruit Count: 20

Registration Number: NCT00538655

Locations: 🇺🇸
CPMC - St. Luke's Hospital ~ 7th Floor/ Addiction Pharmacology Research Lab, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy